Covalon Technologies Ltd. (COV.V)
CAD 3.44
(2.99%)
CAD 3.44
(2.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.48 Million CAD | 50.47% |
| 2022 | -9.14 Million CAD | -1190.52% |
| 2021 | 838.34 Thousand CAD | 113.76% |
| 2020 | -6.09 Million CAD | 26.14% |
| 2019 | -8.24 Million CAD | -609.92% |
| 2018 | 1.61 Million CAD | -10.71% |
| 2017 | 1.81 Million CAD | 161.1% |
| 2016 | -2.96 Million CAD | -291.12% |
| 2015 | -758.15 Thousand CAD | -131.03% |
| 2014 | 2.44 Million CAD | 342.53% |
| 2013 | -1 Million CAD | 72.53% |
| 2012 | -3.66 Million CAD | -1.47% |
| 2011 | -3.61 Million CAD | -76.86% |
| 2010 | -2.04 Million CAD | 58.07% |
| 2009 | -4.87 Million CAD | -30.31% |
| 2008 | -3.74 Million CAD | -9.7% |
| 2007 | -3.41 Million CAD | -46.79% |
| 2006 | -2.32 Million CAD | -26.23% |
| 2005 | -1.84 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.47 Million CAD | 48.61% |
| 2024 Q2 | 1.48 Million CAD | 200.76% |
| 2024 Q3 | 1.47 Million CAD | -0.5% |
| 2023 Q1 | -355.85 Thousand CAD | 91.2% |
| 2023 Q4 | -2.86 Million CAD | -387.24% |
| 2023 Q2 | -721.78 Thousand CAD | -102.83% |
| 2023 FY | -4.52 Million CAD | 50.47% |
| 2023 Q3 | -587.64 Thousand CAD | 18.59% |
| 2022 Q4 | -4.04 Million CAD | -156.52% |
| 2022 Q3 | -1.57 Million CAD | 34.93% |
| 2022 FY | -9.14 Million CAD | -1190.52% |
| 2022 Q1 | -1.09 Million CAD | -124.55% |
| 2022 Q2 | -2.42 Million CAD | -121.31% |
| 2021 Q4 | -487.77 Thousand CAD | -141.29% |
| 2021 Q1 | -253.32 Thousand CAD | 87.21% |
| 2021 FY | 838.34 Thousand CAD | 113.76% |
| 2021 Q2 | 539.05 Thousand CAD | 312.79% |
| 2021 Q3 | 1.18 Million CAD | 119.14% |
| 2020 Q4 | -1.97 Million CAD | -480.94% |
| 2020 Q3 | 519.74 Thousand CAD | 114.11% |
| 2020 FY | -6.09 Million CAD | 26.14% |
| 2020 Q2 | -3.68 Million CAD | -288.09% |
| 2020 Q1 | -948.99 Thousand CAD | 71.1% |
| 2019 Q2 | -114.58 Thousand CAD | 92.71% |
| 2019 FY | -8.24 Million CAD | -609.92% |
| 2019 Q1 | -1.57 Million CAD | -151.35% |
| 2019 Q3 | -3.27 Million CAD | -2761.58% |
| 2019 Q4 | -3.28 Million CAD | -0.15% |
| 2018 Q2 | -479.08 Thousand CAD | -191.54% |
| 2018 Q3 | 2.19 Million CAD | 558.89% |
| 2018 FY | 1.61 Million CAD | -10.71% |
| 2018 Q1 | 523.34 Thousand CAD | 101.8% |
| 2018 Q4 | -625.08 Thousand CAD | -128.43% |
| 2017 Q4 | 259.33 Thousand CAD | -52.09% |
| 2017 FY | 1.81 Million CAD | 161.1% |
| 2017 Q1 | 543.04 Thousand CAD | 125.35% |
| 2017 Q2 | 473.47 Thousand CAD | -12.81% |
| 2017 Q3 | 541.28 Thousand CAD | 14.32% |
| 2016 Q1 | 321.71 Thousand CAD | 142.85% |
| 2016 Q4 | -2.14 Million CAD | -1627.26% |
| 2016 Q3 | -124 Thousand CAD | 87.84% |
| 2016 Q2 | -1.02 Million CAD | -417.08% |
| 2016 FY | -2.96 Million CAD | -291.12% |
| 2015 FY | -758.15 Thousand CAD | -131.03% |
| 2015 Q3 | -111.52 Thousand CAD | -136.56% |
| 2015 Q4 | -750.87 Thousand CAD | -573.3% |
| 2015 Q2 | 305.01 Thousand CAD | 252.08% |
| 2015 Q1 | -200.56 Thousand CAD | 78.43% |
| 2014 Q3 | -218.83 Thousand CAD | -148.83% |
| 2014 Q4 | -929.78 Thousand CAD | -324.88% |
| 2014 FY | 2.44 Million CAD | 342.53% |
| 2014 Q1 | 3.14 Million CAD | 2451.95% |
| 2014 Q2 | 448.14 Thousand CAD | -85.75% |
| 2013 Q2 | -564.2 Thousand CAD | 29.54% |
| 2013 Q3 | 234.32 Thousand CAD | 141.53% |
| 2013 FY | -1 Million CAD | 72.53% |
| 2013 Q4 | 123.19 Thousand CAD | -47.43% |
| 2013 Q1 | -800.74 Thousand CAD | 46.56% |
| 2012 Q3 | -739.53 Thousand CAD | -20.38% |
| 2012 Q4 | -1.49 Million CAD | -102.6% |
| 2012 FY | -3.66 Million CAD | -1.47% |
| 2012 Q1 | -815.59 Thousand CAD | 37.44% |
| 2012 Q2 | -614.33 Thousand CAD | 24.68% |
| 2011 Q2 | -447.72 Thousand CAD | 30.38% |
| 2011 Q1 | -643.06 Thousand CAD | 41.82% |
| 2011 FY | -3.61 Million CAD | -76.86% |
| 2011 Q4 | -1.3 Million CAD | -6.85% |
| 2011 Q3 | -1.22 Million CAD | -172.52% |
| 2010 Q1 | -338.45 Thousand CAD | 59.92% |
| 2010 Q4 | -1.1 Million CAD | -248.33% |
| 2010 Q3 | -317.3 Thousand CAD | -12.2% |
| 2010 Q2 | -282.8 Thousand CAD | 16.44% |
| 2010 FY | -2.04 Million CAD | 58.07% |
| 2009 FY | -4.87 Million CAD | -30.31% |
| 2009 Q1 | -1.45 Million CAD | -40.83% |
| 2009 Q3 | -1.2 Million CAD | 18.93% |
| 2009 Q2 | -1.48 Million CAD | -2.12% |
| 2009 Q4 | -844.45 Thousand CAD | 29.7% |
| 2008 Q1 | -991 Thousand CAD | 23.02% |
| 2008 FY | -3.74 Million CAD | -9.7% |
| 2008 Q3 | -779.92 Thousand CAD | 39.12% |
| 2008 Q2 | -1.28 Million CAD | -29.27% |
| 2008 Q4 | -1.03 Million CAD | -32.1% |
| 2007 Q1 | -452.15 Thousand CAD | 38.9% |
| 2007 Q3 | -1.06 Million CAD | -74.25% |
| 2007 Q4 | -1.28 Million CAD | -21.29% |
| 2007 Q2 | -609.13 Thousand CAD | -34.72% |
| 2007 FY | -3.41 Million CAD | -46.79% |
| 2006 Q3 | -569.2 Thousand CAD | -0.13% |
| 2006 FY | -2.32 Million CAD | -26.23% |
| 2006 Q4 | -740.03 Thousand CAD | -30.01% |
| 2006 Q1 | -445.43 Thousand CAD | 54.36% |
| 2006 Q2 | -568.46 Thousand CAD | -27.62% |
| 2005 Q4 | -975.96 Thousand CAD | -187.8% |
| 2005 Q2 | -338.95 Thousand CAD | -91.7% |
| 2005 FY | -1.84 Million CAD | 0.0% |
| 2005 Q1 | -176.81 Thousand CAD | 0.0% |
| 2005 Q3 | -339.11 Thousand CAD | -0.05% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.35 Million CAD | -33.798% |
| Hemostemix Inc. | -2.33 Million CAD | -92.375% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 1002.973% |
| Kane Biotech Inc. | -3.35 Million CAD | -33.709% |
| MedMira Inc. | -1.94 Million CAD | -130.885% |
| Marvel Biosciences Corp. | -2.31 Million CAD | -93.586% |
| NervGen Pharma Corp. | -17.77 Million CAD | 74.747% |
| XORTX Therapeutics Inc. | -6.38 Million CAD | 29.658% |